Your browser doesn't support javascript.
Operation Warp Speed: implications for global vaccine security.
Lancet Glob Health ; 9(7): e1017-e1021, 2021 07.
Article in English | MEDLINE | ID: covidwho-1294377
ABSTRACT
Several global efforts are underway to develop COVID-19 vaccines, and interim analyses from phase 3 clinical testing have been announced by nine organisations Pfizer, the Gamaleya Research Institute of Epidemiology and Microbiology, Moderna, AstraZeneca, Sinopharm Group, Sinovac Biotech, Johnson & Johnson, Novavax, and CanSino Biologics. The US programme known as Operation Warp Speed provided US$18 billion in funding for development of vaccines that were intended for US populations. Depending on safety and efficacy, vaccines can become available through mechanisms for emergency use, expanded access with informed consent, or full licensure. An important question is how will these Operation Warp Speed vaccines be used for COVID-19 prevention in global health settings? We address some key questions that arise in the transition from US to global vaccine prevention efforts and from ethical and logistical issues to those that are relevant to global vaccine security, justice, equity, and diplomacy.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Global Health / Drug Development / COVID-19 Vaccines / COVID-19 Type of study: Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Humans Country/Region as subject: North America Language: English Journal: Lancet Glob Health Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Global Health / Drug Development / COVID-19 Vaccines / COVID-19 Type of study: Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Humans Country/Region as subject: North America Language: English Journal: Lancet Glob Health Year: 2021 Document Type: Article